Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant AC vs Sequential A->C in High Risk Breast Cancer
NCT00590785Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 1996
- Primary completion
- Jun 1997
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of doxorubicin, cyclophosphamide in breast cancer, sponsored by National Cancer Institute. Started Aug 1996; status: completed.
02
Drugs
doxorubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00590785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00590785.